These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 15776783)

  • 1. Rhabdomyolysis associated with quinacrine therapy in a patient with chronic cutaneous lupus erythematosus.
    Creel N; Werth V
    J Drugs Dermatol; 2005; 4(2):225-7. PubMed ID: 15776783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The association of the two antimalarials chloroquine and quinacrine for treatment-resistant chronic and subacute cutaneous lupus erythematosus.
    Feldmann R; Salomon D; Saurat JH
    Dermatology; 1994; 189(4):425-7. PubMed ID: 7873836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Quinacrine in the treatment of cutaneous lupus erythematosus: practical aspects and a case series].
    González-Sixto B; García-Doval I; Oliveira R; Posada C; García-Cruz MA; Cruces M
    Actas Dermosifiliogr; 2010; 101(1):54-8. PubMed ID: 20109393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of lupus skin involvement with quinacrine and hydroxychloroquine.
    Cavazzana I; Sala R; Bazzani C; Ceribelli A; Zane C; Cattaneo R; Tincani A; Calzavara-Pinton PG; Franceschini F
    Lupus; 2009 Jul; 18(8):735-9. PubMed ID: 19502270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response to antimalarial agents in cutaneous lupus erythematosus: a prospective analysis.
    Chang AY; Piette EW; Foering KP; Tenhave TR; Okawa J; Werth VP
    Arch Dermatol; 2011 Nov; 147(11):1261-7. PubMed ID: 21768444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lupus erythematosus tumidus: response to antimalarial treatment in 36 patients with emphasis on smoking.
    Kreuter A; Gaifullina R; Tigges C; Kirschke J; Altmeyer P; Gambichler T
    Arch Dermatol; 2009 Mar; 145(3):244-8. PubMed ID: 19289751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined mepacrine-hydroxychloroquine treatment in patients with systemic lupus erythematosus and refractory cutaneous and articular activity.
    Ugarte A; Porta S; Ríos R; Martinez-Zapico A; Ortego-Centeno N; Agesta N; Ruiz-Irastorza G
    Lupus; 2018 Sep; 27(10):1718-1722. PubMed ID: 29635998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antimalarial lichenoid tissue reactions in patients with pre-existing lupus erythematosus.
    Geraminejad P; Stone MS; Sontheimer RD
    Lupus; 2004; 13(6):473-7. PubMed ID: 15303576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current treatment of cutaneous lupus erythematosus.
    Werth V
    Dermatol Online J; 2001 Feb; 7(1):2. PubMed ID: 11328623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pigmented oral mucosa due to quinacrine.
    López-Jornet P; Pons-Fuster A
    N Y State Dent J; 2011 Nov; 77(6):49-51. PubMed ID: 22338819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Practice Gaps. Optimizing antimalarial therapy for cutaneous lupus erythematosus: comment on "Response to antimalarial agents in cutaneous lupus erythematosus".
    Callen JP
    Arch Dermatol; 2011 Nov; 147(11):1267-8. PubMed ID: 22106112
    [No Abstract]   [Full Text] [Related]  

  • 12. Yellow skin discoloration induced by quinacrine in a patient with cutaneous lupus erythematosus.
    Vidal D; Altés J; Smandia JA
    Actas Dermosifiliogr; 2013 Jan; 104(1):89-90. PubMed ID: 22831783
    [No Abstract]   [Full Text] [Related]  

  • 13. Recent findings about antimalarials in cutaneous lupus erythematosus: What dermatologists should know.
    Teboul A; Arnaud L; Chasset F
    J Dermatol; 2024 Jul; 51(7):895-903. PubMed ID: 38482997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Combination of antimalarial drugs mepacrine and chloroquine in therapy refractory cutaneous lupus erythematosus].
    von Schmiedeberg S; Rönnau AC; Schuppe HC; Specker C; Ruzicka T; Lehmann P
    Hautarzt; 2000 Feb; 51(2):82-5. PubMed ID: 10743578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Varied responses to and efficacies of hydroxychloroquine treatment according to cutaneous lupus erythematosus subtypes in Japanese patients.
    Ototake Y; Yamaguchi Y; Kanaoka M; Akita A; Ikeda N; Aihara M
    J Dermatol; 2019 Apr; 46(4):285-289. PubMed ID: 30719729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral mucosal pigmentation secondary to treatment with mepacrine, with sparing of the denture bearing area.
    Martin TJ; Sharp I
    Br J Oral Maxillofac Surg; 2004 Aug; 42(4):351-3. PubMed ID: 15225957
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination antimalarials in the treatment of cutaneous dermatomyositis: a retrospective study.
    Ang GC; Werth VP
    Arch Dermatol; 2005 Jul; 141(7):855-9. PubMed ID: 16027300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lupus panniculitis treated by a combination therapy of hydroxychloroquine and quinacrine.
    Chung HS; Hann SK
    J Dermatol; 1997 Sep; 24(9):569-72. PubMed ID: 9350102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resistance to hydroxychloroquine due to smoking in a patient with lupus erythematosus tumidus.
    Hügel R; Schwarz T; Gläser R
    Br J Dermatol; 2007 Nov; 157(5):1081-3. PubMed ID: 17854374
    [No Abstract]   [Full Text] [Related]  

  • 20. Hydroxychloroquine and smoking in patients with cutaneous lupus erythematosus.
    Ezra N; Jorizzo J
    Clin Exp Dermatol; 2012 Jun; 37(4):327-34. PubMed ID: 22582908
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.